Information  X 
Enter a valid email address

Redx Pharma plc (REDX)

  Print   

Tuesday 30 November, 2021

Redx Pharma plc

Redx to Participate at Piper Sandler Conference

RNS Number : 9275T
Redx Pharma plc
30 November 2021
 

REDX PHARMA PLC

("Redx" or the "Company")

 

Redx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

 

Alderley Park, UK, 30 November 2021 - Redx Pharma (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, announces that Lisa Anson, Chief Executive Officer, and Peter Collum, Chief Financial Officer, will be participating at the Piper Sandler 33rd Annual Virtual Healthcare Conference, 30 November to 2 December.

 

A pre-recorded presentation by Lisa Anson can be accessed via the following link: https://bit.ly/3CSvvSV

 

 

For further information, please contact:

 

 

 

Redx Pharma Plc 

 

UK Headquarters

Lisa Anson, Chief Executive Officer

T: +44 (0)1625 469 918

Karl Hård, Head of Investor Relations

[email protected]

 

 

US Office

Peter Collum, Chief Financial Officer

 

 

 

SPARK Advisory Partners (Nominated Adviser)

T: +44 (0)203 368 3550

Matt Davis/ Adam Dawes

 

 

 

WG Partners LLP (Joint Broker)

T: +44 (0)203 705 9330

Claes Spång/ Satheesh Nadarajah/ David Wilson

 

 

 

Panmure Gordon (UK) Limited (Joint Broker)

T: +44 (0)207 886 2500

Rupert Dearden/ Freddy Crossley/ Emma Earl

 

 

 

FTI Consulting

T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin

 

 

About Redx Pharma Plc  

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Initial results were reported in October 2021, with full Phase 1 results expected in 2022.

 

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by the two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by the four strategic transactions from which has emerged the most advanced product candidate pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology. In addition, Redx has forged pre-clinical collaborations with AstraZeneca and Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/    

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKCBBPBDDDDB

a d v e r t i s e m e n t